PainReform Ltd. (PRFX) News
Filter PRFX News Items
PRFX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRFX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PRFX News From Around the Web
Below are the latest news stories about PAINREFORM LTD that investors may wish to consider to help them evaluate PRFX as an investment opportunity.
PainReform Faces Setback in Phase 3 Trial for PRF-110PainReform ( (PRFX) ) has provided an update. PainReform announced that its Phase 3 clinical trial for PRF-110 did not meet its primary endpoint of providing effective postoperative pain relief over 72 hours, as data from the final 24-hour period could not be clarified. Despite this setback, the company is engaging in further R&D efforts to refine the drug’s pharmaco-kinetics and pharmaco-dynamics to potentially support future trials, reflecting their commitment to enhancing pain relief solution |
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. PainReform previously disclosed initial topline data from its Phase 3 clinical trial in which it reported that it demonstrat |
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialTEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis of th |
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementThis notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) advising t |
PainReform cut to Hold at Maxim amid ‘changed’ market dynamicsAs previously reported, Maxim analyst Naz Rahman downgraded PainReform (PRFX) to Hold from Buy. The company is developing PRF-110 to treat post-operative pain and compete in the market with Exparel and Zynrelef, but market dynamics have recently changed, with a generic for Exparel – the market leader – having been approved in July 2024 and impacting the market opportunity for PainReform and its operational ramifications, the analyst tells investors in a research note. Maxim adds that PainReform |
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain ManagementTEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, no |
Top Midday DeclinersTop Midday Decliners |
PainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsTEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the Company originally issued in December 2023 and April 2024, having an exercise price of $4.80 per s |
Upcoming Stock Splits This Week (September 9 to September 13) – Stay InvestedThese are the upcoming stock splits for the week of September 9 to September 13, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). |
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresPRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive Edge Over Leading Pain Management Products TEL AVIV, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful determination of the optimal delivery method for PRF-110 in bunionectomy procedures. This |